MaxCyte, Inc.
NASDAQ•MXCT
CEO: Mr. Maher Masoud
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-07-30
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Contact Information
Market Cap
$84.14M
P/E (TTM)
-1.8
27
Dividend Yield
--
52W High
$3.47
52W Low
$0.64
52W Range
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$6.83M-16.35%
4-Quarter Trend
EPS
-$0.12+9.09%
4-Quarter Trend
FCF
-$7.76M+61.73%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Q3 Revenue Decline Total revenue $6.83M USD for Q3 2025, a 16% decrease versus Q3 2024, driven primarily by core sales contraction.
SPL Revenue Volatility Nine months SPL program revenue $2.88M USD, falling 52% due to uncertain achievement timing of clinical milestones.
SeQure Acquisition Finalized Acquired SeQure in January 2025; preliminary goodwill recorded at $3.55M USD following purchase price allocation adjustments.
Increased Operating Burn Net cash used in operating activities totaled $31.72M USD for nine months, significantly higher than the prior year period.
Risk Factors
Widening Net Loss Nine months net loss reached $(35.03M) USD, increasing from $(30.46M) USD in 2024 due to lower revenue.
Cash Position Decline Cash and equivalents decreased to $12.97M USD by September 30, 2025, reflecting increased operating cash burn.
Restructuring Execution Costs Implemented 34% workforce reduction plan, incurring $3.06M USD restructuring expense during the third quarter period.
Customer Concentration Risk One customer accounted for 51% of total accounts receivable as of September 30, 2025, posing significant concentration risk.
Outlook
Liquidity Runway Secured Existing cash resources expected to fund operating expenses and capital needs for at least the next 12 months.
Strategic Cost Alignment Workforce reduction plan targets 34% reduction to streamline operations and align resources with strategic priorities.
Future Revenue Expectation Expect total revenue growth as customer programs advance, driven by instrument sales and expanding SPL base.
Continued R&D Investment Expect substantial research and development expenses to support customers and develop new product offerings going forward.
Peer Comparison
Revenue (TTM)
$445.38M
$105.66M
$95.11M
Gross Margin (Latest Quarter)
100.0%
92.4%
87.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ARMP | $435.43M | -9.2 | 70.3% | 198.5% |
| CATX | $397.62M | -3.8 | -39.1% | 1.1% |
| FBRX | $354.14M | -9.7 | -75.6% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-7.7%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Mar 24, 2026
EPS:-$0.08
|Revenue:$9.16M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data